VEGFA and Kaposi's sarcoma: In addition, these studies lacked a control arm, making it difficult to quantify the benefit of these agents in this indolent tumor with slow progression.22, 33–35 Interestingly, in patients with KS, HAART plus bevacizumab resulted in an overall response rate of 31%, with three complete responses.36 Despite this finding, anti-VEGF/VEGFR therapy is not currently used routinely in KS likely due to higher response rates with liposomal doxorubicin and taxanes.